The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 25 of the 125 sources its claims cite were checked for support.
Gut microbiota-mediated immunomodulation in tumor
Open accessAbstract
Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.
Overview
CoChat Summary
TL;DR
This review synthesizes evidence that gut microbiota shapes antitumor immunity through innate and adaptive immune cells, microbial PAMPs, metabolites, and secondary lymphoid organ effects. It argues that microbiota modulation may improve immune checkpoint inhibitor (ICI) efficacy, but mechanisms remain unclear and clinical translation requires more rigorous trials.
Key findings
- Cancer patients show altered gut microbial composition versus healthy individuals; for example, colorectal cancer patients have decreased microbial diversity and increased carriage of *Fusobacterium nucleatum*, which is associated with regional lymph node metastasis and shorter survival, while hepatocellular carcinoma patients show increased *Bacteroides* and Ruminococcaceae and lower *Bifidobacterium*.
- Microbiota can promote or suppress tumor immunity: dysbiosis can induce M2-like tumor-associated macrophages, MDSCs, and reduced cytotoxic NK cells, whereas favorable taxa such as *Bifidobacterium*, *Bacteroides fragilis*, and Ruminococcaceae enhance DC activation, CD8+ T cell responses, and IFN-γ production.
- Proposed mechanisms include PAMP–TLR/NF-κB signaling (e.g., LPS, LTA, flagellin), microbiota-derived metabolites such as SCFAs and bile acids, and bacterial translocation affecting secondary lymphoid organs.
- In ICI studies, responders are often enriched for taxa including Ruminococcaceae, *Faecalibacterium*, and *Akkermansia muciniphila*; antibiotics are frequently associated with shorter PFS/OS, including meta-analyses of 2740 and 5565 cancer patients, and responder-derived FMT reversed anti-PD-1 resistance in 6 of 15 patients in one study and produced responses in 3 of 10 refractory melanoma patients in another.
Methods
- Narrative review of preclinical and clinical literature on gut microbiota–tumor immunity interactions and microbiota modulation in ICI therapy.
- No primary data are reported; the paper synthesizes cited mouse, in vitro, and human studies and includes three tables: microbial profiles associated with ICI response, antibiotics use and ICI efficacy, and ongoing clinical trials of microbiome interventions.
- Main analysis is qualitative synthesis rather than systematic review or meta-analysis.
Limitations
- Stated: exact mechanisms remain largely unknown; most studies were done in mice or in vitro; clinical situations are complicated by tumor type/stage, prior treatments, and host factors; immunocyte phenotypes/functions are heterogeneous; the microbiome–cancer relationship is likely bidirectional.
- Stated for antibiotics studies: mostly retrospective without intervention, variable antibiotic class/dose/duration, possible recovery of microbiome before ICI, confounding by infection/inflammation, non-microbiome effects of antibiotics, and small sample sizes.
- Evident: as a narrative review, it lacks a systematic search strategy, formal inclusion criteria, and risk-of-bias assessment; low concordance across microbiota studies is noted and attributed to differing techniques and unadjusted host variables.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
20 Valid · 1 Not valid · 81 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, germ-free mice receiving FMT with a high abundance of Bacteroidales also showed a higher level of CD4+Foxp3+T cells in the spleen [33]”
§ Gut microbiota-mediated immunomodulation in tumor > Potential roles of microbiota in tumor immunity > Adaptive immunity
What the sources say
- Disputedcites [33] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9. sourceExperimental — accuracy not yet measured
Our copy of Sivan et al. (2015) contains no germ-free experiment and no mention of Bacteroidales: its fecal transfers were oral gavage of JAX/TAC fecal suspensions into conventionally raised, tumor-bearing TAC and JAX recipients (Results, Fig. 2A/fig. S1A passage), and its 16S analysis singled out Bifidobacterium as the only taxon significantly associated with antitumor T cell responses (Results, Fig. 3C/table S3 passage). On the regulatory-T-cell readout the paper states the opposite direction: 'we did not observe any difference in the frequency of CD4+ Foxp3+ T cells in tumors isolated from JAX and TAC mice (fig. S5B)' (Results, Bifidobacterium-inoculation passage). Searches for 'germ-free', 'Bacteroidales', and 'Foxp3/spleen/regulatory T cell' returned no passage describing an FMT-induced increase in splenic CD4+Foxp3+ T cells; the spleen is mentioned only for IFN-gamma production by CD8+ T cells and for absence of Bifidobacterium translocation. (LLM, conf=0.62)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals.”
- Also stated in: § Background · plain
“Metagenome analysis revealed a significant difference between the gut microbial composition in cancer patients and healthy individuals.”
§ Gut microbiota-mediated immunomodulation in tumor > Abstract
What the sources say
- Partly supportedcites [7] Abed J, Emgard JEM, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20(2):215–25. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that metagenomic and transcriptomic analyses found Fusobacterium species enriched in human colorectal cancers and adenomas compared with adjacent normal tissue. That supports a narrower microbial difference, but not a significant difference in overall gut microbial composition between cancer patients and healthy individuals. (LLM, conf=0.86)
- Partly supportedcites [8] Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. JNCI-J Natl Cancer I. 2013;105(24):1907–11. sourceExperimental — accuracy not yet measured
The Abstract and Results (passages 2, 3 and 5) report significant differences in fecal microbial diversity and taxa between colorectal cancer cases and controls. The paper used 16S rRNA gene sequencing, not metagenome analysis, and its findings concern colorectal cancer specifically rather than cancer patients generally. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, antibiotics-induced dysbiosis promoted tumor growth via a suppressed level of TNF-α and a subsequent decrease in tumor endothelial adhesion molecules, especially intercellular adhesion molecule 1 (ICAM-1).”
§ Gut microbiota-mediated immunomodulation in tumor > Potential roles of microbiota in tumor immunity > Adaptive immunity
What the sources say
- Supportedcites [37] Jenkins SV, Robeson MSI, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking. Cancer Res. 2019;79(23):5999–6009. source
The Abstract states that antibiotic-induced dysbiosis accelerated B16-F10 melanoma and Lewis Lung carcinoma progression, with mechanistic studies showing this was 'mediated by suppressed TNF-α levels, both locally and systemically, resulting in reduced expression of tumor endothelial adhesion molecules, particularly intercellular adhesion molecule-1 (ICAM-1)' and fewer activated/effector CD8+ T cells. The Introduction (p. 1) and Discussion repeat the same chain, and Results ('TNF-α is suppressed under dysbiotic conditions', p. ~6) quantify the TNF-α reduction locally and in serum, while TNF-α supplementation restored ICAM-1 and reduced tumor growth >60%. The paraphrase matches the source in mechanism, direction and qualifier ('especially ICAM-1'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Analysis of fecal samples revealed that the enrichment of specific gut commensals, such as Bifidobacterium [32] and Ruminococcaceae [33], had a significant positive correlation with CD8+T cell infiltration in the tumor bed or tumor-draining lymph node.”
§ Gut microbiota-mediated immunomodulation in tumor > Potential roles of microbiota in tumor immunity > Adaptive immunity
What the sources say
- Could not verifycites [32] Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84. sourceExperimental — accuracy not yet measured
The passages labeled Abstract report a correlation between fecal B. fragilis abundance and tumor size after CTLA-4 blockade, not between Ruminococcaceae and CD8+ T-cell infiltration. Searches for Ruminococcaceae and for a correlation with CD8+ infiltration found no passage in our copy addressing the claim attributed to citation [33]. (LLM, conf=0.73)
- Supportedcites [33] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9. source
The paper’s main text (indexed under Abstract; page unavailable) reports that fecal Bifidobacterium abundance was significantly and positively associated with activated antigen-specific T-cell accumulation in tumors. It also reports increased intratumoral CD8+ T cells after Bifidobacterium treatment. Citation [32] is attached to Bifidobacterium; the separate Ruminococcaceae claim is attached to [33]. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Iida et al. found that antibiotics decreased CD86 (B7–2) expression in tumor-associated DC [26].”
§ Gut microbiota-mediated immunomodulation in tumor > Potential roles of microbiota in tumor immunity > Adaptive immunity
What the sources say
- Supportedcites [26] Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70. source
Our copy states directly in the Results (Abstract-section passage, Fig. 2 / fig. S4 discussion) that 'ABX also decreased CD86 expression and IL-12B production in tumor-associated DC', matching the attributed claim about antibiotics lowering CD86 on tumor-associated dendritic cells. The parenthetical alias 'B7-2' is standard nomenclature for CD86 and adds no substantive content beyond what the source reports. The same passage situates the finding in MC38 tumors of antibiotic-treated mice under anti-IL-10R/CpG-ODN therapy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
62 more claims · 11 with their cited sources checked
Create a free account to see all 118 claims and to verify the 100 references still open.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The gut microbiota is considered a key player modulating the efficacy of immune checkpoint inhibitor therapy.”
From A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiota-mediated immunomodulation in tumor > Potential roles of microbiota in tumor immunity > Innate immunity
“Gur et al. found that Fap2 protein of Fusobacterium nucleatum could specifically target the inhibitory receptor TIGIT, which is present on human NK cells, and therefore inhibits the cytotoxic effect [9].”
§ Gut microbiota-mediated immunomodulation in tumor > References
“9. Mima K Nishihara R Qian ZR Cao Y Sukawa Y Nowak JA Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis Gut. 2016 65 12 1973 1980 10.1136/gutjnl-2015-310101 26311717 PMC4769120”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiota-mediated immunomodulation in tumor > Gut microbiota and ICIs > Targeting microbiome in ICIs
“As early as 2015, Vetizou et al. found that germ-free mice showed impaired antitumor effects of CTLA-4 blockade while recolonized germ-free mice with bacterial species such as Bacteroides fragilis could recover the therapeutic response [31].”
§ Gut microbiota-mediated immunomodulation in tumor > References
“31. Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9(3059). 10.3389/fimmu.2018.03059 PMC6306491 30619378”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut microbiota-mediated immunomodulation in tumor > Gut microbiota and ICIs > Targeting microbiome in ICIs
“Table: Table 3 Ongoing clinical trials investigating the association between gut microbiome interventions and immunotherapy”
§ Gut microbiota-mediated immunomodulation in tumor > Gut microbiota and ICIs > Targeting microbiome in ICIs
“| Surgically resectable pancreatic cancer (actual enrollment = 0) | Antibiotics in combination with pembrolizumab (single group assignment) | Change in immune activation in pancreatic tumor tissue | NA | Withdrawn (suspended due to primary investigator’s decision) | NCT03891979 |”
Citations
Cites
1 retracted
LI, L., & Ye, J. (2020) · Medicine · doi:10.1097/md.0000000000021788 · Cited by 57 · cited 1×
“2020 [100] Metastatic HCC (n = 65) ICI R showed a high abundance of Clostridiales/Ruminococcaceae in baseline fecal microbiome while NR has a high abundance of Bacteroidales.”
BackgroundRetractedOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Cited by
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
“It has been reported that the gut microbiome activates T cell-mediated responses, resulting in the direct targeting of tumour cells [121].”
BackgroundGut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 588
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Self-citationGuan, Z., Jin, X., Guan, Z., Liu, S., Tao, K., & Luo, L. (2023) · Aging Cell · doi:10.1111/acel.13807 · Cited by 141
Chen, W., Wen, L., Bao, Y., Tang, Z., Zhao, J., Zhang, X., Wei, T., Zhang, J., Ma, T., Zhang, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203894119 · Cited by 116
Metadata
- Authors
- Liu, X., Chen, Y., Zhang, S., & Dong, L.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Zhang, Si
- Dong, Ling
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2021-07-03
- Volume
- 40
- Issue
- 1
- Pages
- 221-221
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC8254267
- OpenAlex
- W3181453493
- Semantic Scholar
- cfa8638e08569996cf8743c276a2ebb6b53ec1e0
- Cited by
- 112
- References
- 139
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 1
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81900482)
- Zhongshan Hospital (2018ZSLC09)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, antitumor immunity, immunomodulation, immune checkpoint inhibitors, microbiota modulation, tumor surveillance, tumor progression, carcinogenesis, metagenomics, cancer patients
- MeSH terms
- Gastrointestinal Microbiome, Humans, Neoplasms, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota-mediated immunomodulation in tumor. https://app.cochat.ai/papers/10.1186/s13046-021-01983-x
- The paper
- Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021). Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-01983-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.